Silencing of the Fas/FasL-driven death receptor pathway by transfection with dominant-negative FADD attenuated the cytotoxic effect of cisplatin in the 833 K testis tumor cell line, supporting again  that activation of Fas/FasL signaling contributes to cisplatin sensitivity of testis tumor cells. The gene discussed is FAS; the disease is neoplasm of testis.